固体腫瘍に対する調査中のKAT6阻害剤:臨床前および初期段階の進展
1Department of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Expert opinion on investigational drugs
|February 17, 2026
まとめ
PrifetrastatのようなKAT6阻害剤は,進行した乳がんやその他の固体腫瘍の治療に有望である. 臨床的意義とより広範な応用の可能性をさらに調査する研究が進められます.
科学分野:
- 腫瘍学 腫瘍学
- 分子生物学は分子生物学である.
- エピジェネティクス エピジェネティクス
背景:
- KAT6AとKAT6B (KAT6) は,MYSTファミリーのヒストンアセチルトランスフェラーゼである.
- KAT6はヒストンH3アセチル化を介して細胞のプロセスを調節する.
- KAT6Aは固体腫瘍で過剰発現し,KAT6はER+乳がんにおけるESR1転写に不可欠である.
研究 の 目的:
- KAT6阻害剤,特にPrifetrastatの臨床的重要性を評価する.
- KAT6阻害剤の応用を,様々な乳がんサブタイプおよび他の固体腫瘍で調査する.
- ディスゲウシアなどの副作用を管理するための戦略を開発し,予測バイオマーカーを特定します.
主な方法:
- ER+乳がん患者におけるPrifetrastatの第I相試験.
- 進んだER+乳がんに対するフルヴェストラントと併用したPrifetrastatのIII相試験.
- 様々なKAT6触媒阻害剤および分解剤の臨床前および臨床開発.
主要な成果:
- Prifetrastatは,第I相試験で有望な有効性と好ましい安全性プロファイルを示し,顕著な副作用としてディスゲウシアを示した.
- 現在進行中の第3相試験は, Prifetrastatの臨床効果に関する重要なデータを提供することが期待されています.
- 多くのKAT6阻害剤は,臨床前および臨床開発を通じて進歩しています.
結論:
- KAT6阻害剤は,ER+進行性乳がんおよび潜在的に他の固体腫瘍に対する有望な治療戦略を表しています.
- 将来の研究は,KAT6阻害剤の応用拡大,副作用の管理,応答バイオマーカーの開発に焦点を当てるべきである.
- KAT6A選択性およびKAT6/7阻害剤の研究は,異なる有効性および安全性プロフィールを明らかにし,KAT6標的治療を進める可能性があります.
関連する概念動画
Inhibition of Cdk Activity
6.1K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
Tumor Progression
7.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.5K
mTOR Signaling and Cancer Progression
4.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.9K
Tumor Immunotherapy
2.0K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
Preclinical Development: Overview
6.1K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.1K


